---
title: Enhance home walking and balance
nct_id: NCT06617884
phase: NA
status: RECRUITING
sponsor: Forschungszentrum Juelich
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06617884"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06617884"
last_fetched: "2026-05-10T14:07:41.216Z"
source: "Parkinson's Pathways (curated)"
---
# Enhance home walking and balance

**Goal (in five words):** Enhance home walking and balance

**Official Title:** Comparison of Two Home-based Gait and Balance Trainings With Different Training Frequencies in Patients With Parkinson's Disease and Ataxia

**Trial ID:** [NCT06617884](https://clinicaltrials.gov/study/NCT06617884)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Forschungszentrum Juelich
- **Target Enrollment:** 80 participants
- **Start Date:** 2023-01-04
- **Completion Date:** 2025-12
- **Conditions:** Ataxia, Parkinson Disease
- **Interventions:** Gait and balance training
- **Intervention Types:** OTHER

## Summary For Families

Researchers are testing whether different schedules of home-based gait and balance exercises can improve walking, stability, and daily mobility in people with Parkinson's disease or cerebellar ataxia, and whether one frequency is more effective at reducing fall risk. Participants follow guided at-home training that targets stepping, coordination, timing, and leg strength to retrain balance responses and gait patterns through repetition and motor learning, this is a non-drug approach meant to complement medications like levodopa rather than replace them. Adults 18 to 75 with a clinical diagnosis of idiopathic Parkinson's syndrome or cerebellar ataxia who can walk at least four meters at home are eligible, while those with frequent falls (one or more per week), other major motor-impacting illnesses, severe psychiatric disease, addiction, poor general health, or inability to consent are excluded; Parkinson's participants must be able to be measured during their on-medication phase.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 75 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* clinical diagnosis of cerebellar ataxia or idiopathic Parkinson's syndrome
* opportunity to walk a distance of four meters unhindered at home

Exclusion Criteria:

* other diseases with an impact on motor skills
* severe primary psychiatric illnesses
* current drug or alcohol addiction
* consumptive diseases
* poor general condition
* increased risk of falling (anamnestic fall frequency of ≥ 1x per week or as assessed by the attending physician)
* incapacitated patients in official or court custody or patients unable to give consent
* for PD patients taking medication: not being able to carry out the measurement in the on-phase of the medication
```

## Locations (1)

- Universitätsklinikum Düsseldorf, Institut für Klinische Neurowissenschaften und Medizinische Psychologie, Düsseldorf, North Rhine-Westphalia, Germany _(51.2232, 6.7793)_
  - Martina Minnerop, PD Dr. med. — (CONTACT) — +49 2461 61 2125 — m.minnerop@fz-juelich.de
  - Clara Rentz, M. Sc. — (CONTACT) — +49 2461 61 2125 — c.rentz@fz-juelich.de
  - Martina Minnerop, PD Dr. med. — (PRINCIPAL_INVESTIGATOR)

## Central Contacts

- Martina Minnerop, PD Dr. med. — (CONTACT) — +49246161-2125 — m.minnerop@fz-juelich.de
- Clara Rentz, M. Sc. — (CONTACT) — +492461612125 — c.rentz@fz-juelich.de

---

*Canonical: https://parkinsonspathways.com/trial/NCT06617884*  
*HTML version: https://parkinsonspathways.com/trial/NCT06617884*  
*Source data: https://clinicaltrials.gov/study/NCT06617884*